Oryzon Genomics SA (ORY) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.031x

Based on the latest financial reports, Oryzon Genomics SA (ORY) has a cash flow conversion efficiency ratio of -0.031x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.41 Million ≈ $-2.82 Million USD) by net assets (€78.54 Million ≈ $91.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oryzon Genomics SA net asset quality index to measure how much of total assets are equity-financed.

Oryzon Genomics SA - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Oryzon Genomics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Oryzon Genomics SA to evaluate the quality of earnings relative to operating cash generation.

Oryzon Genomics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Oryzon Genomics SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Eltel AB ST:ELTEL	0.251x
Akmerkez Gayrimenkul Yatirim Ortakligi AS IS:AKMGY	0.014x
Taaleri Oyj HE:TAALA	0.010x
Kuo Yang Construction Co Ltd TW:2505	0.002x
DCX Systems Limited NSE:DCXINDIA	0.002x
CHTC Helon Co Ltd SHE:000677	-0.004x
Asia Cement KO:002030	0.021x
TTFB Co Ltd TWO:2729	0.072x

Annual Cash Flow Conversion Efficiency for Oryzon Genomics SA (2013–2025)

The table below shows the annual cash flow conversion efficiency of Oryzon Genomics SA from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Oryzon Genomics SA.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€117.85 Million ≈ $137.78 Million	€-2.36 Million ≈ $-2.75 Million	-0.020x	+69.41%
2024-12-31	€87.04 Million ≈ $101.76 Million	€-5.69 Million ≈ $-6.65 Million	-0.065x	-829.69%
2023-12-31	€81.77 Million ≈ $95.60 Million	€-574.96K ≈ $-672.19K	-0.007x	+72.38%
2022-12-31	€72.57 Million ≈ $84.84 Million	€-1.85 Million ≈ $-2.16 Million	-0.025x	+49.97%
2021-12-31	€71.26 Million ≈ $83.31 Million	€-3.63 Million ≈ $-4.24 Million	-0.051x	+19.79%
2020-12-31	€75.93 Million ≈ $88.77 Million	€-4.82 Million ≈ $-5.63 Million	-0.063x	-29.04%
2019-12-31	€80.02 Million ≈ $93.55 Million	€-3.93 Million ≈ $-4.60 Million	-0.049x	-233.08%
2018-12-31	€45.13 Million ≈ $52.76 Million	€-666.09K ≈ $-778.73K	-0.015x	+89.20%
2017-12-31	€34.43 Million ≈ $40.25 Million	€-4.71 Million ≈ $-5.50 Million	-0.137x	+37.94%
2016-12-31	€22.73 Million ≈ $26.57 Million	€-5.01 Million ≈ $-5.85 Million	-0.220x	-1262.00%
2015-12-31	€27.59 Million ≈ $32.26 Million	€523.14K ≈ $611.61K	0.019x	-97.83%
2014-12-31	€13.89 Million ≈ $16.24 Million	€12.13 Million ≈ $14.18 Million	0.873x	+6.01%
2013-12-31	€14.73 Million ≈ $17.22 Million	€12.13 Million ≈ $14.18 Million	0.823x	--

About Oryzon Genomics SA

MC:ORY Spain Biotechnology

Market Cap

$263.71 Million

€225.56 Million EUR

Market Cap Rank

#16298 Global

#105 in Spain

Share Price

€2.91

Change (1 day)

-0.27%

52-Week Range

€2.57 - €3.82

All Time High

€5.14